Omnicell (OMCL) Receives a Buy from Colliers Securities

In a report released today, Eugene Mannheimer from Colliers Securities reiterated a Buy rating on Omnicell (OMCL – Research Report), with a price target of $164.00. The company's shares closed last Thursday at $139.95. According to TipRanks.com, Mannheimer is a 4-star analyst with an average return of 19.9% and a 54.4% success rate. Mannheimer covers the Technology sector, focusing on stocks such as Computer Programs and Systems, NextGen Healthcare, and Castlight Health. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omnicell with a $166.33 average price target, representing an 11.6% upside. In a report issued on July 26, BTIG also reiterated a Buy rating on the stock with a $175.00 price target. See today’s analyst top recommended stocks >> Based on Omnicell's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $252 million and net profit of $14.13 million. In comparison, last year the company earned revenue of $230 million and had a net profit of $11.31 million. Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is neutral on the stock. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA. Read More on OMCL: VICI Properties (VICI) Gets a Buy Rating from Deutsche Bank JonesTrading Keeps Their Buy Rating on Cassava Sciences (SAVA) Overstock (OSTK) Gets a Buy Rating from Wedbush Check Point: Solid Q2, but Competition Is Growing Mizuho Securities Reiterates Their Buy Rating on Allegro MicroSystems (ALGM) The post Omnicell (OMCL) Receives a Buy from Colliers Securities appeared first on TipRanks Financial Blog.

In a report released today, Eugene Mannheimer from Colliers Securities reiterated a Buy rating on Omnicell (OMCL – Research Report), with a price target of $164.00. The company's shares closed last Thursday at $139.95.

According to TipRanks.com, Mannheimer is a 4-star analyst with an average return of 19.9% and a 54.4% success rate. Mannheimer covers the Technology sector, focusing on stocks such as Computer Programs and Systems, NextGen Healthcare, and Castlight Health.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Omnicell with a $166.33 average price target, representing an 11.6% upside. In a report issued on July 26, BTIG also reiterated a Buy rating on the stock with a $175.00 price target.

Based on Omnicell's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $252 million and net profit of $14.13 million. In comparison, last year the company earned revenue of $230 million and had a net profit of $11.31 million.

Based on the recent corporate insider activity of 38 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence; platform and interoperability; central pharmacy dispensing; medication adherence; population health; and point of care automation. The company was founded by Randall A. Lipps in September 1992 and is headquartered in Mountain View, CA.

Read More on OMCL:

  • VICI Properties (VICI) Gets a Buy Rating from Deutsche Bank
  • JonesTrading Keeps Their Buy Rating on Cassava Sciences (SAVA)
  • Overstock (OSTK) Gets a Buy Rating from Wedbush
  • Check Point: Solid Q2, but Competition Is Growing
  • Mizuho Securities Reiterates Their Buy Rating on Allegro MicroSystems (ALGM)

The post Omnicell (OMCL) Receives a Buy from Colliers Securities appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Wedbush Thinks Axcella Health's Stock is Going to Recover

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $11.00. The company's shares closed last Thursday at $3.56, close to its 52-week low of $3.03. According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 2.5% and a 34.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $11.80 average price target. See today’s analyst top recommended stocks >> The company has a one-year high of $6.84 and a one-year low of $3.03. Currently, Axcella Health has an average volume of 321.9K. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA. Read More on AXLA: Omnicell (OMCL) Receives a Buy from Colliers Securities VICI Properties (VICI) Gets a Buy Rating from Deutsche Bank JonesTrading Keeps Their Buy Rating on Cassava Sciences (SAVA) Overstock (OSTK) Gets a Buy Rating from Wedbush Check Point: Solid Q2, but Competition Is Growing The post Wedbush Thinks Axcella Health's Stock is Going to Recover appeared first on TipRanks Financial Blog.

In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Axcella Health (AXLA – Research Report), with a price target of $11.00. The company's shares closed last Thursday at $3.56, close to its 52-week low of $3.03.

According to TipRanks.com, Moussatos is a 3-star analyst with an average return of 2.5% and a 34.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Eiger Biopharmaceuticals, and BioMarin Pharmaceutical.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Axcella Health with a $11.80 average price target.

The company has a one-year high of $6.84 and a one-year low of $3.03. Currently, Axcella Health has an average volume of 321.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Axcella Health, Inc. is a biotechnology company, which engages in the research and development of novel multifactorial interventions to support health and address dysregulated metabolism across a broad spectrum of consumers and patients who have limited options. Its product pipeline includes AXA1665, AXA1125, AXA1957, AXA2678, and AXA4010. The company was founded by Noubar B. Afeyan, Geoffrey von Maltzahn, and David A. Berry on August 27, 2008 and is headquartered in Cambridge, MA.

Read More on AXLA:

  • Omnicell (OMCL) Receives a Buy from Colliers Securities
  • VICI Properties (VICI) Gets a Buy Rating from Deutsche Bank
  • JonesTrading Keeps Their Buy Rating on Cassava Sciences (SAVA)
  • Overstock (OSTK) Gets a Buy Rating from Wedbush
  • Check Point: Solid Q2, but Competition Is Growing

The post Wedbush Thinks Axcella Health's Stock is Going to Recover appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.